Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.
Maurice Perol, MD, Léon Bérard Cancer Center
Advertisement
Articles by Maurice Perol, MD, Léon Bérard Cancer Center
Advertisement
Latest Updated Articles
Standard of Care for EGFR+ ES-NSCLCOctober 20th 2020
Practical Implications of ADAURA in NSCLCOctober 20th 2020
Molecular Testing in Early-Stage NSCLCOctober 20th 2020
Testing for EGFR in NSCLC WorldwideOctober 20th 2020
Adjuvant Approaches in EGFR+ NSCLCOctober 20th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
3
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5